

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (original) A pharmaceutical composition comprising celecoxib; a first excipient which is a propylene glycol fatty acid monoester; a second excipient selected from the group consisting of a polyethylene glycol, a polyoxyl castor oil, and a polysorbate; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polysorbate, a sorbitan fatty acid monoester, a poloxamer, a polyethylene glycol, a polyethylene glycol fatty acid monoester, and a polyoxyl castor oil.

Claims 2-82 (canceled)

83 (new) The pharmaceutical composition of Claim 1, wherein:

- (a) said second excipient is selected from the group consisting of polyethylene glycol 400, polyoxyl 35 castor oil and polysorbate 80;
- (b) said third excipient is selected from the group consisting of propylene glycol monolaurate, polysorbate 80, sorbitan monolaurate, poloxamer 331, polyethylene glycol 400 and polyethylene glycol 20 stearate;
- (c) said first excipient is propylene glycol monolaurate;
- (d) said first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; or
- (e) said second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

84 (new) A pharmaceutical composition comprising celecoxib; a first excipient which is a poloxamer; a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyoxamer, and a plant oil; and a third excipient selected from the group consisting

of a propylene glycol fatty acid monoester, a poloxamer, a polysorbate and a sorbitan fatty acid monoester.

85 (new) The pharmaceutical composition of Claim 84, wherein:

- (a) said second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331 and sesame oil;
- (b) said third excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polysorbate 80, sesame oil and sorbital monolaurate;
- (c) said first excipient is poloxamer 331;
- (d) said first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; or
- (e) said second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

86 (new) A pharmaceutical composition comprising celecoxib; a first excipient which is a polyethylene glycol; a second excipient selected from the group consisting of a polyethylene glycol, a polyoxyl castor oil and a sorbitan fatty acid monoester; and a third excipient selected from the group consisting of a polyethylene glycol, a sorbitan fatty acid monoester and a propylene glycol fatty acid monoester.

87 (new) The pharmaceutical composition of Claim 86, wherein:

- (a) said second excipient is selected from the group consisting of polyethylene glycol 400, polyoxyl 35 castor oil and sorbitan monolaurate;
- (b) said third excipient is selected from the group consisting of polyethylene glycol 400, sorbitan monolaurate and propylene glycol monolaurate;
- (c) said first excipient is polyethylene glycol 400;
- (d) said first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; or

(e) said second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

88 (new) A pharmaceutical composition comprising celecoxib; a first excipient which is a sorbitan fatty acid monoester; a second excipient selected from the group consisting of a polyethylene glycol and a polysorbate; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyoxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate, a plant oil or a sorbitan fatty acid monoester.

89 (new) The pharmaceutical composition of Claim 88, wherein:

- (a) said second excipient is selected from the group consisting of polyethylene glycol 400 and polysorbate 80;
- (b) said third excipient is selected from the group of propylene glycol laurate, polyoxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sesame oil and sorbitan monolaurate;
- (c) said first excipient is sorbitan monolaurate;
- (d) said first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; or
- (e) said second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

90 (new) A pharmaceutical composition comprising celecoxib; a first excipient which is a polyoxyl castor oil; a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate and a sorbitan fatty acid monoester; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyoxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate, a plant oil and a sorbitan fatty acid monoester.

91 (new) The pharmaceutical composition of Claim 90, wherein:

- (a) said second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80 and sorbitan monolaurate;
- (b) said third excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sorbitan monolaurate and sesame oil;
- (c) said first excipient is polyoxyl 35 castor oil;
- (d) said first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; or
- (e) said second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.

92 (new) A pharmaceutical composition comprising celecoxib; a first excipient which is a polysorbate; a second excipient selected from the group consisting of a propylene glycol fatty acid monoester, a poloxamer, a polyethylene glycol, a polyoxyl castor oil, a polysorbate and a sorbitan fatty acid monoester; and a third excipient selected from the group consisting of a propylene glycol fatty acid monoester, a polyethylene glycol, a polyoxyl castor oil, a polysorbate a plant oil, a sorbitan fatty acid monoester and a poloxamer.

93 (new) The pharmaceutical composition of Claim 92, wherein:

- (a) said second excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80 and sorbitan monolaurate;
- (b) said third excipient is selected from the group consisting of propylene glycol monolaurate, poloxamer 331, polyethylene glycol 400, polyoxyl 35 castor oil, polysorbate 80, sorbitan monolaurate and sesame oil;
- (c) said first excipient is polysorbate 80;
- (d) said first excipient comprises about 60% to about 70% by weight of the first, second and third excipients; or

(e) said second excipient comprises about 20% to about 30% by weight of the first, second and third excipients and the third excipient comprises about 5% to about 15% by weight of the first, second and third excipients.